Glaxo to Sell Rare Disease Gene Therapies to Private Biotech – Zacks.com
Zacks.com |
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
Zacks.com Glaxo's rare disease gene therapies include marketed drug Strimvelis, a gene therapy for children with ADA-SCID which is an autosomal recessive metabolic disorder that causes immunodeficiency, along with some pipeline candidates including late-stage … Orchard Therapeutics to buy GSK's rare disease gene therapy portfolio Gene Therapy and Antisense Drugs Developing New Market By 2025 Gene Therapy Market Overview, Type, Manufacturers, Regions, Industry Analysis and Forecast by 2022 |
